Impact of gout flare on health-related quality of life: a multi-center cross-sectional study in Thailand
Issued Date
2025-01-01
Resource Type
ISSN
07703198
eISSN
14349949
Scopus ID
2-s2.0-85217361314
Pubmed ID
39888479
Journal Title
Clinical Rheumatology
Rights Holder(s)
SCOPUS
Bibliographic Citation
Clinical Rheumatology (2025)
Suggested Citation
Dilokthornsakul P., Louthrenoo W., Chevaisrakul P., Siripaitoon B., Jatuworapruk K., Upakdee N., Buttham B., Towiwat P. Impact of gout flare on health-related quality of life: a multi-center cross-sectional study in Thailand. Clinical Rheumatology (2025). doi:10.1007/s10067-025-07339-6 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/105325
Title
Impact of gout flare on health-related quality of life: a multi-center cross-sectional study in Thailand
Corresponding Author(s)
Other Contributor(s)
Abstract
Objective: Although the 5-level EQ-5D version (EQ-5D-5L) instrument has been used to determine health-related quality of life and health utility in gout, it is used in comparing health utility among gout flare (GF) and non-gout flare (non-GF) patients is still limited. This study aimed to compare health utility among GF and non-GF patients in Thailand. Methods: In this multi-center cross-sectional study, patients with GF and non-GF were interviewed for the EQ-5D5L and EQ-Visual Analog Scale (VAS) instruments by rheumatologists or trained research staffs. Patients with GF were subdivided into 2 subgroups (those who received no treatment and those who received treatment less than 48 h after GF episode). Results: Two hundred and sixteen patients (108 GF and 108 non-GF patients), males in 90.28%, were included. The gout disease duration was significantly longer in the non-GF than in the GF groups (median, 10 vs 5 years; p = 0.004). There was no difference in the tophi present between the two groups. When compared with the non-GF group, the GF patients significantly had low health utility (0.34 ± 0.36 vs. 0.89 ± 0.15, p < 0.001) and EQ-VAS score (54.73 ± 25.14 vs. 84.06 ± 13.38, p < 0.001). In the subgroup analysis of the non-GF group, there was insignificant health utility and EQ-VAS score between those with tophi and those without tophi (0.87 ± 0.14 vs. 0.90 ± 0.15, p = 0.124 and 83.36 ± 14.92 vs. 84.33 ± 12.83, p = 0.938, respectively). Conclusion: This study found that GF clearly had a substantial impact on patients’ quality of life. Targeted interventions in managing GF patients to improve their health outcomes are needed. (Table presented.)